Literature DB >> 22509432

Design of substituted bis-Tetrahydrofuran (bis-THF)-derived Potent HIV-1 Protease Inhibitors, Protein-ligand X-ray Structure, and Convenient Syntheses of bis-THF and Substituted bis-THF Ligands.

Arun K Ghosh1, Cuthbert D Martyr, Melinda Steffey, Yuan-Fang Wang, Johnson Agniswamy, Masayuki Amano, Irene T Weber, Hiroaki Mitsuya.   

Abstract

We investigated substituted bis-THF-derived HIV-1 protease inhibitors in order to enhance ligand-binding site interactions in the HIV-1 protease active site. In this context, we have carried out convenient syntheses of optically active bis-THF and C4-substituted bis-THF ligands using a [2,3]-sigmatropic rearrangement as the key step. The synthesis provided convenient access to a number of substituted bis-THF derivatives. Incorporation of these ligands led to a series of potent HIV-1 protease inhibitors. Inhibitor 23c turned out to be the most potent (K(i) = 2.9 pM; IC(50) = 2.4 nM) among the inhibitors. An X-ray structure of 23c-bound HIV-1 protease showed extensive interactions of the inhibitor with the protease active site, including a unique water-mediated hydrogen bond to the Gly-48 amide NH in the S2 site.

Entities:  

Year:  2011        PMID: 22509432      PMCID: PMC3325757          DOI: 10.1021/ml100289m

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  17 in total

1.  Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation.

Authors:  Fengling Liu; Andrey Y Kovalevsky; John M Louis; Peter I Boross; Yuan-Fang Wang; Robert W Harrison; Irene T Weber
Journal:  J Mol Biol       Date:  2006-03-20       Impact factor: 5.469

Review 2.  Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of hiv protease inhibitors that combat drug resistance.

Authors:  Arun K Ghosh; Perali Ramu Sridhar; Nagaswamy Kumaragurubaran; Yasuhiro Koh; Irene T Weber; Hiroaki Mitsuya
Journal:  ChemMedChem       Date:  2006-09       Impact factor: 3.466

3.  Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.

Authors:  Yuan-Fang Wang; Yunfeng Tie; Peter I Boross; Jozsef Tozser; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Med Chem       Date:  2007-08-16       Impact factor: 7.446

4.  Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.

Authors:  A K Ghosh; J F Kincaid; D E Walters; Y Chen; N C Chaudhuri; W J Thompson; C Culberson; P M Fitzgerald; H Y Lee; S P McKee; P M Munson; T T Duong; P L Darke; J A Zugay; W A Schleif; M G Axel; J Lin; J R Huff
Journal:  J Med Chem       Date:  1996-08-16       Impact factor: 7.446

5.  A simple, continuous fluorometric assay for HIV protease.

Authors:  M V Toth; G R Marshall
Journal:  Int J Pept Protein Res       Date:  1990-12

6.  Stereoselective and efficient synthesis of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol.

Authors:  Peter J L M Quaedflieg; Bart R R Kesteleyn; Piet B T P Wigerinck; Nicolaas M F Goyvaerts; Robert Jan Vijn; Constantinus S M Liebregts; Jaap H M H Kooistra; Claudia Cusan
Journal:  Org Lett       Date:  2005-12-22       Impact factor: 6.005

7.  Stereoselective photochemical 1,3-dioxolane addition to 5-alkoxymethyl-2(5H)-furanone: synthesis of bis-tetrahydrofuranyl ligand for HIV protease inhibitor UIC-94017 (TMC-114).

Authors:  Arun K Ghosh; Sofiya Leshchenko; Marcus Noetzel
Journal:  J Org Chem       Date:  2004-11-12       Impact factor: 4.354

8.  Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.

Authors:  Yasuhiro Koh; Hirotomo Nakata; Kenji Maeda; Hiromi Ogata; Geoffrey Bilcer; Thippeswamy Devasamudram; John F Kincaid; Peter Boross; Yuan-Fang Wang; Yunfeng Tie; Patra Volarath; Laquasha Gaddis; Robert W Harrison; Irene T Weber; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 9.  Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.

Authors:  Arun K Ghosh; Bruno D Chapsal; Irene T Weber; Hiroaki Mitsuya
Journal:  Acc Chem Res       Date:  2007-08-28       Impact factor: 22.384

Review 10.  Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease.

Authors:  Arun K Ghosh
Journal:  J Med Chem       Date:  2009-04-23       Impact factor: 7.446

View more
  15 in total

Review 1.  Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.

Authors:  Arun K Ghosh; Heather L Osswald; Gary Prato
Journal:  J Med Chem       Date:  2016-01-22       Impact factor: 7.446

Review 2.  Tetrahydrofuran, tetrahydropyran, triazoles and related heterocyclic derivatives as HIV protease inhibitors.

Authors:  Arun K Ghosh; David D Anderson
Journal:  Future Med Chem       Date:  2011-07       Impact factor: 3.808

Review 3.  Highly resistant HIV-1 proteases and strategies for their inhibition.

Authors:  Irene T Weber; Daniel W Kneller; Andres Wong-Sam
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

Review 4.  Investigational protease inhibitors as antiretroviral therapies.

Authors:  Narasimha M Midde; Benjamin J Patters; Pss Rao; Theodore J Cory; Santosh Kumar
Journal:  Expert Opin Investig Drugs       Date:  2016-08-02       Impact factor: 6.206

5.  Design, synthesis, biological evaluation and X-ray structural studies of HIV-1 protease inhibitors containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligands.

Authors:  Arun K Ghosh; Cuthbert D Martyr; Luke A Kassekert; Prasanth R Nyalapatla; Melinda Steffey; Johnson Agniswamy; Yuan-Fang Wang; Irene T Weber; Masayuki Amano; Hiroaki Mitsuya
Journal:  Org Biomol Chem       Date:  2015-10-14       Impact factor: 3.876

6.  GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.

Authors:  Nicole S Delino; Manabu Aoki; Hironori Hayashi; Shin-Ichiro Hattori; Simon B Chang; Yuki Takamatsu; Cuthbert D Martyr; Debananda Das; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

7.  Disubstituted Bis-THF Moieties as New P2 Ligands in Nonpeptidal HIV-1 Protease Inhibitors.

Authors:  Konrad Hohlfeld; Cyrille Tomassi; Jörg Kurt Wegner; Bart Kesteleyn; Bruno Linclau
Journal:  ACS Med Chem Lett       Date:  2011-03-31       Impact factor: 4.345

8.  Nature Inspired Molecular Design: Stereoselective Synthesis of Bicyclic and Polycyclic Ethers for Potent HIV-1 Protease Inhibitors.

Authors:  Arun K Ghosh; Margherita Brindisi
Journal:  Asian J Org Chem       Date:  2018-06-08       Impact factor: 3.319

9.  Estimation of genetic diversity and population structure in Tinospora cordifolia using SSR markers.

Authors:  Suchita Lade; Veena Pande; Tikam Singh Rana; Hemant Kumar Yadav
Journal:  3 Biotech       Date:  2020-06-16       Impact factor: 2.406

10.  Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Studies.

Authors:  Arun K Ghosh; Cuthbert D Martyr; Heather L Osswald; Venkat Reddy Sheri; Luke A Kassekert; Shujing Chen; Johnson Agniswamy; Yuan-Fang Wang; Hironori Hayashi; Manabu Aoki; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2015-08-25       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.